As many as 30 patients with early stage prostate cancer could be treated with a new, minimally-invasive device in a clinical trial expected to begin at two U.S. hospitals later this year, says Paul Chipperton, CEO of Profound Medical, Inc. (PMI).
The trial will evaluate the safety and effectiveness of the company’s innovative MR-guided thermal ultrasound device, which Chipperton says has the potential to treat patients three to six times faster with greater accuracy and fewer side effects than existing options. Click here to view video and read full report.